이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder

자폐 장애와 관련된 과민성을 가진 소아 환자의 장기 유지 치료에서 아리피프라졸의 안전성 및 효능

The purpose of this study is to determine whether pediatric participants with irritability associated with autistic disorder who have responded to aripiprazole treatment will experience a relapse significantly later when continuing therapy with aripiprazole than will participants who receive placebo.

연구 개요

상태

완전한

정황

개입 / 치료

연구 유형

중재적

등록 (실제)

215

단계

  • 4단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Alabama
      • Dothan, Alabama, 미국, 36303
        • Harmonex Neuroscience Research, Inc
    • Arizona
      • Phoenix, Arizona, 미국, 85006
        • Southwest Autism Research And Resource Center
    • California
      • Costa Mesa, California, 미국, 92626
        • Clinical Innovations, Inc.
      • Glendale, California, 미국, 91206
        • Behavioral Research Specialists, Llc
      • Palo Alto, California, 미국, 94306
        • Abbey Neuropsychology Clinic
      • San Francisco, California, 미국, 94143
        • Ucsf - Lppi
      • Stanford, California, 미국, 94305
        • Stanford University School Of Medicine
    • District of Columbia
      • Washington D.C., District of Columbia, 미국, 20010
        • Children'S National Medical Center
    • Florida
      • Gainesville, Florida, 미국, 32607
        • Sarkis Clinical Trials
      • Hialeah, Florida, 미국, 33012
        • Palm Springs Research Institute
      • Maitland, Florida, 미국, 32751
        • Florida Clinical Research Center, Llc
      • Miami, Florida, 미국, 33155
        • Miami Children'S Hospital
      • Tampa, Florida, 미국, 33613
        • University Of South Florida
    • Georgia
      • Smyrna, Georgia, 미국, 30080
        • Institute For Behavioral Medicine, Llc
    • Idaho
      • Coeur d'Alene, Idaho, 미국, 83814
        • Kootenai Behavioral Health Center
    • Kentucky
      • Louisville, Kentucky, 미국, 40202
        • Kosair Charities Pediatric Clinical Research Unit
    • Louisiana
      • Shreveport, Louisiana, 미국, 71103
        • Lsu Health Sciences Center
    • Massachusetts
      • Newton, Massachusetts, 미국, 02459
        • Neurocare, Inc.
    • Michigan
      • Bloomfield Hills, Michigan, 미국, 48302
        • Neurobehavioral Medicine Group
    • Nevada
      • Las Vegas, Nevada, 미국, 89128
        • Center For Psychiatry And Behavioral Medicine, Inc
    • New Jersey
      • Gibbsboro, New Jersey, 미국, 08026
        • Clinical Research Center Of New Jersey
      • Toms River, New Jersey, 미국, 08755
        • Children'S Specialized Hosp
    • New York
      • Stony Brook, New York, 미국, 11794
        • Stony Brook University School Of Medicine
    • North Carolina
      • Chapel Hill, North Carolina, 미국, 27517
        • Unc Chapel Hill
    • Ohio
      • Cleveland, Ohio, 미국, 44106
        • University Hospitals Case Medical Center
      • Cleveland, Ohio, 미국, 44104
        • Cleveland Clinic
      • Columbus, Ohio, 미국, 43210
        • The Ohio State University Nisonger Center
    • Oklahoma
      • Oklahoma City, Oklahoma, 미국, 73116
        • Cutting Edge Research Group
      • Oklahoma City, Oklahoma, 미국, 73117
        • Ou Physician'S Child Study Center
      • Tulsa, Oklahoma, 미국, 74104
        • Tulsa Clinical Research, Llc
    • Oregon
      • Gresham, Oregon, 미국, 97030
        • Cyn3rgy Research
    • Pennsylvania
      • Philadelphia, Pennsylvania, 미국, 19124
        • Drexel University College Of Medicine
      • Pittsburgh, Pennsylvania, 미국, 15203
        • Western Psychiatric Institute And Clinic
    • Tennessee
      • Kingsport, Tennessee, 미국, 37660
        • Holston Medical Group
    • Texas
      • DeSoto, Texas, 미국, 75115
        • Insite Clinical Research
    • Utah
      • Clinton, Utah, 미국, 84015
        • Ericksen Research And Development
    • Virginia
      • Norfolk, Virginia, 미국, 23510
        • Childrens Specialty Gr., Pllc
      • Richmond, Virginia, 미국, 23298
        • Virginia Treatment Center For Children

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

6년 (어린이)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Key Inclusion Criteria:

  • Male or female children or adolescents, 6 to 17 years of age, inclusive, at the time of the baseline visit
  • Meets current diagnostic criteria of the Diagnostic and Statistical Manual-of Mental Disorders IV-Text Revised for autistic disorder and displays behaviors such as tantrums, aggression, self-injurious behavior, or a combination of these problems. Diagnosis of autistic disorder will be confirmed by the Autism Diagnostic Interview-Revised.
  • Participant or designated guardian or caregiver is able to comprehend and satisfactorily comply with the protocol requirements, in the opinion of the investigator.
  • Demonstrates behaviors such as tantrums, aggression, or self-injury or a combination of these problems
  • An Aberrant Behavior Checklist Irritability subscale score ≥18 AND a Clinical Global Impressions Severity score ≥4 at the Screening and Baseline Visits.
  • Mental age of at least 24 months

Key Exclusion Criteria:

  • Treatment resistant to neuroleptic medication, based on lack of therapeutic response to 2 different neuroleptics after treatment for at least 3 weeks each.
  • Previous treatment with aripiprazole for at least 3 weeks duration at an adequate daily dose, without demonstrating a clinically meaningful response.
  • Lifetime diagnosis of bipolar disorder, psychosis, or schizophrenia, or a current diagnosis of major depressive disorder
  • Diagnosis of Pervasive Developmental Disorder-Not Otherwise Specified, Asperger's Syndrome, Rett's Syndrome, childhood disintegrative disorder, or Fragile X Syndrome
  • History of neuroleptic malignant syndrome
  • At significant risk for suicide based on history or routine psychiatric status examination
  • A seizure within the past year
  • History of severe head trauma or stroke
  • History or current evidence of any unstable medical conditions that would expose the patient to undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the course of the trial
  • Weight lower than 15 kg
  • Known allergy or hypersensitivity to aripiprazole or other dihidrocarbostyrils
  • History of a clinically significant low white blood cell count or a drug-induced leukopenia/neutropenia
  • Any other medically significant abnormal laboratory test or vital sign result or electrocardiogram finding

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
위약 비교기: 위약

Tablets, oral, 0 mg, once daily, 16 weeks

실험적: 아리피프라졸

Tablets, oral, 2-15 mg, once daily, 13-42 weeks

다른 이름들:
  • 어빌리파이
  • BMS-337039

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Percentage of Patients Relapsing by Week 16
기간: From end of Phase 1 (Date of randomization) to Week 16 of Phase 2 and end of treatment

Time of relapse=date when patient meets relapse criteria. There are 4 definitions for relapse: 1. Patient meets the following criteria for 2 consecutive visits: (a) Aberrant Behavior Checklist Irritability score ≥25% than score at end of Phase 1 AND (b) Clinical Global Impression Improvement scale rating of 'Much Worse' or 'Very Much Worse' relative to rating at end of Phase 1. If relapse criteria met at 1 visit, 2nd visit should occur in about 1 week to reevaluate whether relapse criteria are still met. 2. Patient discontinues for "Lost to Follow-up" after a visit in which he or she met Definition 1 criteria (a&b). 3. Patient begins a prohibited drug (whether a study investigator or outside source prescribed) to treat worsening symptoms of irritability of autistic disorder after a visit where patient met Definition 1 criteria (a&b). 4. Patient discontinues due to hospitalization for worsening symptoms of irritability or due to lack of efficacy based on investigator's assessment.

From end of Phase 1 (Date of randomization) to Week 16 of Phase 2 and end of treatment

2차 결과 측정

결과 측정
측정값 설명
기간
Adjusted Mean Change From Baseline to Week 16 on the Aberrant Behavior Checklist Irritability (ABC-I) Subscale Score (Last Observation Carried Forward [LOCF])
기간: From Baseline (end of Phase 1) to Week 16 of Phase 2

ABC is an informant-based checklist used to assess and classify problem behaviors of children and adolescents with mental retardation. The 58 items are rated on a 4-point scale (0=not at all a problem to 3=the problem is severe in degree), and resolve into 5 subscales: 1) irritability, agitation; 2) lethargy, social withdrawal; 3) stereotypic behavior; 4) hyperactivity, noncompliance; and 5) inappropriate speech. The ABC can be completed by parents, special educators, psychologists, direct caregivers, nurses, and others knowing the participant. Psychometric assessment of the ABC indicates that its subscales have high internal consistency, adequate reliability, and established validity. The ABC-I Subscale Score ranges from 0 to 45, with a negative change in score signifying improvement. LOCF data set includes data recorded at a given visit or, if no observation was recorded at that visit, data carried forward from the prior visit. chg=change; BL=baseline; APR=aripiprazole; vs=versus.

From Baseline (end of Phase 1) to Week 16 of Phase 2
Change From Baseline in Mean Clinical Global Impression Improvement (CGI-I) Scale Score at Week 16 (Last Observation Carried Forward [LOCF])
기간: From Baseline (end of Phase 1) to Week 16 of Phase 2

CG-I rating scale permits global evaluation of patient's improvement over time. At baseline (BL), CGI Severity of Illness assessment is performed, in which the clinician rates severity of patient's condition on a 7-point scale ranging from 1=no symptoms to 7=very severe symptoms. Higher total score=worse symptoms. At subsequent visits, clinician assesses patient's improvement relative to symptoms at baseline on CGI-I 7-point scale ranging from 1=very much improved to 7=very much worse. Since the drug targets irritability symptoms, the CGI focuses on severity of irritability secondary to autistic disorder. Lower score=more improved symptoms. LOCF data set includes data recorded at a given visit or, if nothing recorded, data areccarried forward from the prior visit. For secondary endpoints (endpt), hierarchical testing was used to keep overall experiment-wise type I error rate to <=0.05. diff=difference; IS=irritability scale; PA=primary analysis; signif=significance/significantly.

From Baseline (end of Phase 1) to Week 16 of Phase 2
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Discontinuation During Phase 1
기간: Up to 26 weeks

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.

Up to 26 weeks

기타 결과 측정

결과 측정
측정값 설명
기간
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Treatment-related AEs During Phase 2
기간: Weekly from Weeks 1 through 16 (end of treatment) of Phase 2

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.

Weekly from Weeks 1 through 16 (end of treatment) of Phase 2

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2011년 3월 7일

기본 완료 (실제)

2012년 6월 20일

연구 완료 (실제)

2012년 6월 20일

연구 등록 날짜

최초 제출

2010년 10월 22일

QC 기준을 충족하는 최초 제출

2010년 10월 22일

처음 게시됨 (추정된)

2010년 10월 25일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 3일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 9일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • CN138-603

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .